"Lactams, Macrocyclic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
LACTAMS forming compounds with a ring size of approximately 1-3 dozen atoms.
Descriptor ID |
D047029
|
MeSH Number(s) |
D02.065.589.327 D04.345.295
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Lactams, Macrocyclic".
Below are MeSH descriptors whose meaning is more specific than "Lactams, Macrocyclic".
This graph shows the total number of publications written about "Lactams, Macrocyclic" by people in this website by year, and whether "Lactams, Macrocyclic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1993 | 0 | 1 | 1 |
1994 | 0 | 1 | 1 |
1996 | 0 | 2 | 2 |
1997 | 0 | 1 | 1 |
1998 | 0 | 1 | 1 |
1999 | 0 | 2 | 2 |
2000 | 0 | 1 | 1 |
2001 | 0 | 2 | 2 |
2002 | 0 | 1 | 1 |
2004 | 0 | 1 | 1 |
2005 | 0 | 3 | 3 |
2006 | 1 | 0 | 1 |
2009 | 0 | 3 | 3 |
2010 | 0 | 1 | 1 |
2011 | 0 | 1 | 1 |
2013 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lactams, Macrocyclic" by people in Profiles.
-
Voruganti S, Lacroix JC, Rogers CN, Rogers J, Matts RL, Hartson SD. The anticancer drug AUY922 generates a proteomics fingerprint that is highly conserved among structurally diverse Hsp90 inhibitors. J Proteome Res. 2013 Aug 02; 12(8):3697-706.
-
Egger ME, Huang JS, Yin W, McMasters KM, McNally LR. Inhibition of autophagy with chloroquine is effective in melanoma. J Surg Res. 2013 Sep; 184(1):274-81.
-
Gilbert JA, Adhikari LJ, Lloyd RV, Halfdanarson TR, Muders MH, Ames MM. Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors. Pancreas. 2013 Apr; 42(3):411-21.
-
Davenport J, Manjarrez JR, Peterson L, Krumm B, Blagg BS, Matts RL. Gambogic acid, a natural product inhibitor of Hsp90. J Nat Prod. 2011 May 27; 74(5):1085-92.
-
Matts RL, Brandt GE, Lu Y, Dixit A, Mollapour M, Wang S, Donnelly AC, Neckers L, Verkhivker G, Blagg BS. A systematic protocol for the characterization of Hsp90 modulators. Bioorg Med Chem. 2011 Jan 01; 19(1):684-92.
-
Gilbert JA, Adhikari LJ, Lloyd RV, Rubin J, Haluska P, Carboni JM, Gottardis MM, Ames MM. Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors. Endocr Relat Cancer. 2010 Sep; 17(3):623-36.
-
Jadhav VD, Duerfeldt AS, Blagg BS. Design, synthesis, and biological activity of bicyclic radester analogues as Hsp90 inhibitors. Bioorg Med Chem Lett. 2009 Dec 15; 19(24):6845-50.
-
Duerfeldt AS, Brandt GE, Blagg BS. Design, synthesis, and biological evaluation of conformationally constrained cis-amide Hsp90 inhibitors. Org Lett. 2009 Jun 04; 11(11):2353-6.
-
Duerfeldt AS, Blagg BS. Hydrating for resistance to radicicol. ACS Chem Biol. 2009 Apr 17; 4(4):245-7.
-
Valks GC, McRobbie G, Lewis EA, Hubin TJ, Hunter TM, Sadler PJ, Pannecouque C, De Clercq E, Archibald SJ. Configurationally restricted bismacrocyclic CXCR4 receptor antagonists. J Med Chem. 2006 Oct 19; 49(21):6162-5.